Multiple Sclerosis

Patients who have both multiple sclerosis (MS) and depression may have a higher risk of death and vascular disease compared with people who only have 1 or neither of those conditions.

Patients with multiple sclerosis (MS) who have recovered from COVID-19 and received the B-cell depleting therapy ocrelizumab for at least 1 year were observed to still have T-cell responses.

Investigators found that biomarkers for neurodegeneration and inflammation could also aid providers in detecting declines in cognition and information processing speed in patients with multiple sclerosis (MS) over a 5-year period.

The single-leg heel test was able to differentiate between weaker and stronger limbs in patients with multiple sclerosis (MS) and in healthy controls, suggesting that the test could prove useful for identifying impaired muscle performance.

Using artificial intelligence (AI) effectively may help to revolutionize the diagnosis, monitoring, and treatment of multiple sclerosis (MS), as well as optimizing understanding of the immune-mediated disease.

Results of an observational study suggest retinal nerve fiber layer atrophy and the presence of oligoclonal bands may serve as biomarkers for cognitive decline in patients with multiple sclerosis (MS).

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

Investigators explored the associations between body weight and pediatric-onset multiple sclerosis.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

Research indicates those with pediatric-onset multiple sclerosis (POMS) may have reduced memory performance compared with healthy controls.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.

Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.

Results of a retrospective observational study indicate good adherence to disease-modifying therapies (DMTs) for multiple sclerosis (MS) is associated with better outcomes among veterans with the disease.

Spinal cord stimulation (SCS) to treat pain in persons with multiple sclerosis (MS) was the focus of a recent literature review out of Italy.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.

MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.

Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.

Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.

A new analysis may give clinicians a more in-depth understanding of an individual patient’s multiple sclerosis (MS) disease course.